{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:07:24Z","timestamp":1791511644549,"version":"4.3.4"},"reference-count":144,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>There are large disparities in the impact of diabetes on cardiovascular disease (CVD) risk and outcomes by sex and gender. Achieving health equity requires understanding risks and medication efficacy in female patients, especially now, as novel pharmacologic treatments are transforming the diabetes and CVD treatment landscape. This review examines 2 bodies of research that can inform sex differences in CVD in patients with diabetes: female-specific risk factors for CVD and sex-related limitations of clinical trial research in evaluating novel diabetes and CVD treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two literature searches were performed using Ovid Medline(R) All. The first retrieved manuscripts covering sex and gender differences related to CVD risk and therapies and diabetes. The second focused on randomized controlled trial data on sex\/gender differences and GLP-1\/SGLT-2\/DPP-4 drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Female-specific risk factors for CVD include early menarche, premature or early menopause, irregular cycles and polycystic ovary syndrome; pregnancy; adverse pregnancy outcomes; history of breast cancer; and autoimmune diseases. Clinical trials of novel pharmacological treatments for diabetes and CVD have undersampled female populations, and clinical characteristics of male and female participants have differed significantly. Thus, evidence to evaluate potential sex differences in treatment efficacy and side effects has been lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>To improve health of female patients with diabetes, sex-specific cardiovascular risk factors should be taken into account in screening and treatment decisions. Further, studies of cardiovascular and diabetes medications must ensure adequate representation by sex and report participant characteristics and outcomes by sex.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgae655","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T15:23:10Z","timestamp":1726845790000},"page":"e2167-e2177","source":"Crossref","is-referenced-by-count":11,"title":["Sex-Specific Cardiovascular Risk Factors and Treatment in Females With T2DM and CVD: Developments and Knowledge Gaps"],"prefix":"10.1210","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4067-3432","authenticated-orcid":false,"given":"Erin S","family":"LeBlanc","sequence":"first","affiliation":[{"name":"Science Programs Department, Kaiser Permanente Center for Health Research NW , Portland, OR 97227 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neon","family":"Brooks","sequence":"additional","affiliation":[{"name":"Science Programs Department, Kaiser Permanente Center for Health Research NW , Portland, OR 97227 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Davies","sequence":"additional","affiliation":[{"name":"Science Programs Department, Kaiser Permanente Center for Health Research NW , Portland, OR 97227 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4294-8081","authenticated-orcid":false,"given":"Ranee","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University School of Medicine , Durham, NC 27701 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"issue":"7533","key":"2024111804013141700_dgae655-B1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/bmj.38678.389583.7C","article-title":"Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies","volume":"332","author":"Huxley","year":"2006","journal-title":"BMJ"},{"issue":"9","key":"2024111804013141700_dgae655-B2","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1007\/s00125-019-4926-x","article-title":"Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals","volume":"62","author":"Ohkuma","year":"2019","journal-title":"Diabetologia"},{"issue":"13","key":"2024111804013141700_dgae655-B3","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/eurheartj\/ehz898","article-title":"Sex and gender in cardiovascular medicine: presentation and outcomes of acute coronary syndrome","volume":"41","author":"Haider","year":"2020","journal-title":"Eur Heart J"},{"issue":"12","key":"2024111804013141700_dgae655-B4","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/eurjpc\/zwad133","article-title":"Higher risk of adverse cardiovascular outcomes in females with type 2 diabetes Mellitus: an Umbrella review of systematic reviews","volume":"30","author":"Yaow","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"2024111804013141700_dgae655-B5","author":"CDC"},{"issue":"7","key":"2024111804013141700_dgae655-B6","doi-asserted-by":"crossref","first-page":"e2222070","DOI":"10.1001\/jamanetworkopen.2022.22070","article-title":"Sex differences in the progression of metabolic risk factors in diabetes development","volume":"5","author":"Yoshida","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2024111804013141700_dgae655-B7","doi-asserted-by":"crossref","first-page":"e003159","DOI":"10.1136\/bmjdrc-2022-003159","article-title":"Higher burden of cardiometabolic and socioeconomic risk factors in women with type 2 diabetes: an analysis of the Glycemic Reduction Approaches in Diabetes (GRADE) baseline cohort","volume":"11","author":"Gulanski","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2024111804013141700_dgae655-B8","author":"CDC"},{"issue":"1","key":"2024111804013141700_dgae655-B9","doi-asserted-by":"crossref","first-page":"e14987","DOI":"10.1111\/dme.14987","article-title":"Sex disparities in medication prescribing amongst patients with type 2 diabetes mellitus managed in primary care","volume":"40","author":"Ambro\u017e","year":"2023","journal-title":"Diabet Med"},{"issue":"1","key":"2024111804013141700_dgae655-B10","doi-asserted-by":"crossref","first-page":"2166101","DOI":"10.1080\/14017431.2023.2166101","article-title":"Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial","volume":"57","author":"Ferrannini","year":"2023","journal-title":"Scand Cardiovasc J"},{"issue":"4","key":"2024111804013141700_dgae655-B11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1053\/j.semvascsurg.2023.10.005","article-title":"A systematic review of disparities in the medical management of atherosclerotic cardiovascular disease in females","volume":"36","author":"Simioni","year":"2023","journal-title":"Semin Vasc Surg"},{"issue":"15","key":"2024111804013141700_dgae655-B12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/heartjnl-2023-323722","article-title":"Sex differences in the intensity of statin prescriptions at initiation in a primary care setting","volume":"110","author":"Kiss","year":"2024","journal-title":"Heart"},{"issue":"4","key":"2024111804013141700_dgae655-B13","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/dom.15443","article-title":"Risk factor control and incident cardiovascular disease in patients with diabetes: sex-specific relations","volume":"26","author":"Wang","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2024111804013141700_dgae655-B14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJM199107253250401","article-title":"Differences in the use of procedures between women and men hospitalized for coronary heart disease","volume":"325","author":"Ayanian","year":"1991","journal-title":"N Engl J Med"},{"issue":"14","key":"2024111804013141700_dgae655-B15","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1161\/CIRCULATIONAHA.121.056025","article-title":"Cardiac surgery in women in the current era: what are the gaps in care?","volume":"144","author":"Cho","year":"2021","journal-title":"Circulation"},{"key":"2024111804013141700_dgae655-B16","author":"News AHA"},{"issue":"10292","key":"2024111804013141700_dgae655-B17","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/S0140-6736(21)00684-X","article-title":"The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030","volume":"397","author":"Vogel","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"2024111804013141700_dgae655-B18","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1161\/CIR.0b013e318287cf2f","article-title":"Fifteen-year trends in awareness of heart disease in women: results of a 2012 American Heart Association national survey","volume":"127","author":"Mosca","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"2024111804013141700_dgae655-B19","doi-asserted-by":"crossref","first-page":"658","DOI":"10.7326\/M23-2788","article-title":"Newer pharmacologic treatments in adults with type 2 diabetes: a clinical guideline from the American College of Physicians","volume":"177","author":"Qaseem","year":"2024","journal-title":"Ann Intern Med"},{"issue":"2","key":"2024111804013141700_dgae655-B20","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1093\/ejendo\/lvad170","article-title":"Cardiovascular disease in transgender people: a systematic review and meta-analysis","volume":"190","author":"van Zijverden","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2024111804013141700_dgae655-B21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1515\/HMBCI.2010.084","article-title":"Mechanisms of estrogen protection in diabetes and metabolic disease","volume":"4","author":"Cignarella","year":"2010","journal-title":"Horm Mol Biol Clin Investig"},{"key":"2024111804013141700_dgae655-B22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.maturitas.2017.08.003","article-title":"Gaps, limitations and new insights on endogenous estrogen and follicle stimulating hormone as related to risk of cardiovascular disease in women traversing the menopause: a narrative review","volume":"104","author":"El Khoudary","year":"2017","journal-title":"Maturitas"},{"issue":"12","key":"2024111804013141700_dgae655-B23","doi-asserted-by":"crossref","first-page":"e012406","DOI":"10.1161\/JAHA.119.012406","article-title":"Age at menarche and risk of cardiovascular disease outcomes: findings from the national heart lung and blood institute-sponsored women's ischemia syndrome evaluation","volume":"8","author":"Lee","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"2024111804013141700_dgae655-B24","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/CIRCRESAHA.121.319895","article-title":"Pregnancy and reproductive risk factors for cardiovascular disease in women","volume":"130","author":"O'Kelly","year":"2022","journal-title":"Circ Res"},{"issue":"1","key":"2024111804013141700_dgae655-B25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/jwh.2018.6998","article-title":"Early menarche and risk of metabolic syndrome: a systematic review and meta-analysis","volume":"28","author":"Kim","year":"2019","journal-title":"J Womens Health (Larchmt)"},{"issue":"1","key":"2024111804013141700_dgae655-B26","doi-asserted-by":"crossref","first-page":"e0280929","DOI":"10.1371\/journal.pone.0280929","article-title":"Relationship between age at menarche and metabolic diseases in Korean postmenopausal women: the Korea National Health and Nutrition Examination Survey 2016-2018","volume":"18","author":"Jung","year":"2023","journal-title":"PLoS ONE"},{"issue":"6","key":"2024111804013141700_dgae655-B27","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1210\/jc.2003-032046","article-title":"The prevalence and features of the polycystic ovary syndrome in an unselected population","volume":"89","author":"Azziz","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024111804013141700_dgae655-B28","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/humupd\/dml036","article-title":"A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome","volume":"12","author":"Boomsma","year":"2006","journal-title":"Hum Reprod Update"},{"key":"2024111804013141700_dgae655-B29","doi-asserted-by":"crossref","first-page":"m3502","DOI":"10.1136\/bmj.m3502","article-title":"Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review","volume":"371","author":"Okoth","year":"2020","journal-title":"BMJ"},{"issue":"9","key":"2024111804013141700_dgae655-B30","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1210\/jc.2005-0151","article-title":"Predictors of endothelial dysfunction in young women with polycystic ovary syndrome","volume":"90","author":"Kravariti","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024111804013141700_dgae655-B31","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1210\/jc.2003-031096","article-title":"Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease","volume":"89","author":"Boulman","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024111804013141700_dgae655-B32","doi-asserted-by":"crossref","first-page":"356.e1\u2013","DOI":"10.1016\/j.amjmed.2005.10.059","article-title":"Endothelial dysfunction in PCOS: role of obesity and adipose hormones","volume":"119","author":"Carmina","year":"2006","journal-title":"Am J Med"},{"issue":"7","key":"2024111804013141700_dgae655-B33","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1055\/s-0029-1242715","article-title":"Polycystic ovarian syndrome and the risk of cardiovascular disease and thrombosis","volume":"35","author":"Mak","year":"2009","journal-title":"Seminars in Thrombosis and Hemostasis"},{"issue":"16","key":"2024111804013141700_dgae655-B34","doi-asserted-by":"crossref","first-page":"e030105","DOI":"10.1161\/JAHA.123.030105","article-title":"Associations of oral contraceptive use with cardiovascular disease and all-cause death: evidence from the UK Biobank Cohort Study","volume":"12","author":"Dou","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2024111804013141700_dgae655-B35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jacc.2008.09.042","article-title":"Contraceptive hormone use and cardiovascular disease","volume":"53","author":"Shufelt","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2024111804013141700_dgae655-B36","doi-asserted-by":"crossref","first-page":"e003769","DOI":"10.1161\/JAHA.116.003769","article-title":"Association of age at menopause with incident heart failure: a prospective cohort study and meta-analysis","volume":"5","author":"Appiah","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"2024111804013141700_dgae655-B37","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamacardio.2016.2415","article-title":"Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis","volume":"1","author":"Muka","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"11","key":"2024111804013141700_dgae655-B38","doi-asserted-by":"crossref","first-page":"e006713","DOI":"10.1161\/JAHA.117.006713","article-title":"Duration of reproductive life span, age at menarche, and age at menopause are associated with risk of cardiovascular disease in women","volume":"6","author":"Ley","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"24","key":"2024111804013141700_dgae655-B39","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2019.19191","article-title":"Association of premature natural and surgical menopause with incident cardiovascular disease","volume":"322","author":"Honigberg","year":"2019","journal-title":"JAMA"},{"issue":"8","key":"2024111804013141700_dgae655-B40","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/GME.0000000000000171","article-title":"Early severe vasomotor menopausal symptoms are associated with diabetes","volume":"21","author":"Herber-Gast","year":"2014","journal-title":"Menopause"},{"issue":"6","key":"2024111804013141700_dgae655-B41","doi-asserted-by":"crossref","first-page":"e0157417","DOI":"10.1371\/journal.pone.0157417","article-title":"Association of vasomotor and other menopausal symptoms with risk of cardiovascular disease: a systematic review and meta-analysis","volume":"11","author":"Muka","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"2024111804013141700_dgae655-B42","doi-asserted-by":"crossref","first-page":"zsw052","DOI":"10.1093\/sleep\/zsw052","article-title":"Sleep characteristics and carotid atherosclerosis among midlife women","volume":"40","author":"Thurston","year":"2017","journal-title":"Sleep"},{"key":"2024111804013141700_dgae655-B43","doi-asserted-by":"crossref","first-page":"100448","DOI":"10.1016\/j.coemr.2023.100448","article-title":"Vasomotor symptoms and their links to cardiovascular disease risk","volume":"30","author":"Carson","year":"2023","journal-title":"Curr Opin Endocr Metab Res"},{"issue":"3","key":"2024111804013141700_dgae655-B44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.6118\/jmm.20030","article-title":"Vasomotor symptoms: more than temporary menopausal symptoms","volume":"26","author":"Ryu","year":"2020","journal-title":"J Menopausal Med"},{"issue":"6","key":"2024111804013141700_dgae655-B45","doi-asserted-by":"crossref","first-page":"783","DOI":"10.5665\/sleep.1874","article-title":"Sleep is associated with the metabolic syndrome in a multi-ethnic cohort of midlife women: the SWAN Sleep Study","volume":"35","author":"Hall","year":"2012","journal-title":"Sleep"},{"issue":"179","key":"2024111804013141700_dgae655-B46","first-page":"1","article-title":"Fertility of men and women aged 15-49 in the United States: National Survey of Family Growth, 2015\u20132019","author":"Martinez","year":"2023","journal-title":"Natl Health Stat Rep"},{"issue":"6","key":"2024111804013141700_dgae655-B47","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1177\/2047487318818265","article-title":"Parity and risk of maternal cardiovascular disease: a dose-response meta-analysis of cohort studies","volume":"26","author":"Li","year":"2019","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"2024111804013141700_dgae655-B48","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1186\/s12889-017-4519-x","article-title":"Age at first birth and risk of later-life cardiovascular disease: a systematic review of the literature, its limitation, and recommendations for future research","volume":"17","author":"Rosendaal","year":"2017","journal-title":"BMC Public Health"},{"issue":"2","key":"2024111804013141700_dgae655-B49","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11886-022-01830-1","article-title":"Markers of cardiovascular risk associated with pregnancy","volume":"25","author":"Quesada","year":"2023","journal-title":"Curr Cardiol Rep"},{"issue":"6","key":"2024111804013141700_dgae655-B50","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/CIRCULATIONAHA.112.128751","article-title":"Elevated blood pressure in pregnancy and subsequent chronic disease risk","volume":"127","author":"M\u00e4nnist\u00f6","year":"2013","journal-title":"Circulation"},{"issue":"22","key":"2024111804013141700_dgae655-B51","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/heartjnl-2012-303237","article-title":"Miscarriage and future maternal cardiovascular disease: a systematic review and meta-analysis","volume":"99","author":"Oliver-Williams","year":"2013","journal-title":"Heart"},{"issue":"8","key":"2024111804013141700_dgae655-B52","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/CIRCULATIONAHA.118.036748","article-title":"Cardiovascular disease-related morbidity and mortality in women with a history of pregnancy complications","volume":"139","author":"Grandi","year":"2019","journal-title":"Circulation"},{"issue":"22","key":"2024111804013141700_dgae655-B53","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1016\/j.jacc.2019.09.052","article-title":"Long-term cardiovascular risk in women with hypertension during pregnancy","volume":"74","author":"Honigberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2024111804013141700_dgae655-B54","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00125-019-4840-2","article-title":"Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis","volume":"62","author":"Kramer","year":"2019","journal-title":"Diabetologia"},{"issue":"12","key":"2024111804013141700_dgae655-B55","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1093\/aje\/kwab206","article-title":"Maternal cardiovascular and cerebrovascular health after placental abruption: a systematic review and meta-analysis (CHAP-SR)","volume":"190","author":"Ananth","year":"2021","journal-title":"Am J Epidemiol"},{"issue":"19","key":"2024111804013141700_dgae655-B56","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jacc.2022.03.335","article-title":"Cardiovascular risk factors mediate the long-term maternal risk associated with hypertensive disorders of pregnancy","volume":"79","author":"Stuart","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2024111804013141700_dgae655-B57","doi-asserted-by":"crossref","first-page":"e072112","DOI":"10.1136\/bmj-2022-072112","article-title":"Adverse pregnancy outcomes and long term risk of ischemic heart disease in mothers: national cohort and co-sibling study","volume":"380","author":"Crump","year":"2023","journal-title":"BMJ"},{"issue":"6","key":"2024111804013141700_dgae655-B58","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jamainternmed.2024.0276","article-title":"Adverse pregnancy outcomes and long-term mortality in women","volume":"184","author":"Crump","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"7","key":"2024111804013141700_dgae655-B59","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1111\/dom.15612","article-title":"Association of gestational diabetes with long-term risk of premature mortality, and cardiovascular outcomes and risk factors: a retrospective cohort analysis in the UK Biobank","volume":"26","author":"Michalopoulou","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2024111804013141700_dgae655-B60","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1089\/jwh.2023.0026","article-title":"Adverse pregnancy outcomes and future metabolic syndrome","volume":"32","author":"Ehrenthal","year":"2023","journal-title":"J Womens Health (Larchmt)"},{"issue":"7","key":"2024111804013141700_dgae655-B61","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1001\/jamacardio.2019.1746","article-title":"Association of conventional cardiovascular risk factors with cardiovascular disease after hypertensive disorders of pregnancy: analysis of the Nord-Tr\u00f8ndelag Health Study","volume":"4","author":"Haug","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"9677","key":"2024111804013141700_dgae655-B62","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(09)60731-5","article-title":"Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis","volume":"373","author":"Bellamy","year":"2009","journal-title":"Lancet"},{"key":"2024111804013141700_dgae655-B63","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.diabres.2018.04.008","article-title":"Hyperglycemia in pregnancy and its implications for a woman's future risk of cardiovascular disease","volume":"145","author":"Retnakaran","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"2024111804013141700_dgae655-B64","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.2337\/dc22-2226","article-title":"Distinct insulin physiology trajectories in euglycemic pregnancy and gestational diabetes mellitus","volume":"46","author":"Thaweethai","year":"2023","journal-title":"Diabetes Care"},{"issue":"6","key":"2024111804013141700_dgae655-B65","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1046\/j.1523-1755.1998.00217.x","article-title":"Temporal relationships between hormonal and hemodynamic changes in early human pregnancy","volume":"54","author":"Chapman","year":"1998","journal-title":"Kidney Int"},{"issue":"7","key":"2024111804013141700_dgae655-B66","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/heartjnl-2015-308476","article-title":"Cardiac output and related haemodynamics during pregnancy: a series of meta-analyses","volume":"102","author":"Meah","year":"2016","journal-title":"Heart"},{"key":"2024111804013141700_dgae655-B67","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.5888\/pcd16.190105","article-title":"Hypertension and diabetes in non-pregnant women of reproductive age in the United States","volume":"16","author":"Azeez","year":"2019","journal-title":"Preventing Chronic Disease"},{"issue":"18","key":"2024111804013141700_dgae655-B68","doi-asserted-by":"crossref","first-page":"e902","DOI":"10.1161\/CIR.0000000000000961","article-title":"Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a scientific statement from the American Heart Association","volume":"143","author":"Parikh","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"2024111804013141700_dgae655-B69","doi-asserted-by":"crossref","first-page":"439.e1\u2013","DOI":"10.1016\/j.ajog.2020.05.036","article-title":"Two-day postpartum compared with 4- to 12-week postpartum glucose tolerance testing for women with gestational diabetes","volume":"223","author":"Werner","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"2024111804013141700_dgae655-B70","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/AOG.0000000000002849","article-title":"ACOG Committee Opinion No. 736: optimizing postpartum care","volume":"132","author":"McKinney","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"11","key":"2024111804013141700_dgae655-B71","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/CIRCULATIONAHA.121.053730","article-title":"American Heart Association's Life's simple 7: lifestyle recommendations, polygenic risk, and lifetime risk of coronary heart disease","volume":"145","author":"Hasbani","year":"2022","journal-title":"Circulation"},{"issue":"3","key":"2024111804013141700_dgae655-B72","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10549-017-4282-9","article-title":"Risk of death from cardiovascular disease following breast cancer: a systematic review","volume":"164","author":"Gernaat","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"2024111804013141700_dgae655-B73","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1200\/JCO.21.01736","article-title":"Risk of cardiovascular disease in women with and without breast cancer: the pathways heart study","volume":"40","author":"Greenlee","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"2024111804013141700_dgae655-B74","first-page":"e27917","article-title":"Breast cancer and the cardiovascular disease: a narrative review","volume":"14","author":"Cherukuri","year":"2022","journal-title":"Cureus"},{"key":"2024111804013141700_dgae655-B75","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.critrevonc.2016.10.011","article-title":"Cancer treatment induced metabolic syndrome: improving outcome with lifestyle","volume":"108","author":"Westerink","year":"2016","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"8","key":"2024111804013141700_dgae655-B76","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","article-title":"Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association","volume":"137","author":"Mehta","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"2024111804013141700_dgae655-B77","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1161\/CIRCRESAHA.121.319877","article-title":"Cardiovascular implications of immune disorders in women","volume":"130","author":"Moran","year":"2022","journal-title":"Circ Res"},{"issue":"12","key":"2024111804013141700_dgae655-B78","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.24092","article-title":"Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"59","author":"Avi\u00f1a-Zubieta","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2024111804013141700_dgae655-B79","doi-asserted-by":"crossref","first-page":"5438287","DOI":"10.1155\/2019\/5438287","article-title":"Inflammation and dysmetabolism in systemic autoimmune diseases","volume":"2019","author":"Afeltra","year":"2019","journal-title":"J Immunol Res"},{"issue":"25_suppl_2","key":"2024111804013141700_dgae655-B80","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"issue":"25","key":"2024111804013141700_dgae655-B81","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"SCORE2 working group and ESC Cardiovascular risk collaboration","year":"2021","journal-title":"Eur Heart J"},{"issue":"25","key":"2024111804013141700_dgae655-B82","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","article-title":"SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions","volume":"42","author":"SCORE2-OP working group and ESC Cardiovascular risk collaboration","year":"2021","journal-title":"Eur Heart J"},{"issue":"24","key":"2024111804013141700_dgae655-B83","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"2024111804013141700_dgae655-B84","doi-asserted-by":"crossref","first-page":"e0210329","DOI":"10.1371\/journal.pone.0210329","article-title":"Cardiovascular risk prediction models for women in the general population: a systematic review","volume":"14","author":"Baart","year":"2019","journal-title":"PLoS One"},{"issue":"10","key":"2024111804013141700_dgae655-B85","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.cardfail.2020.09.233","article-title":"The role of reproductive factors in risk prediction of incident heart failure in White and Black women: the women's health initiative","volume":"26","author":"Mehta","year":"2020","journal-title":"J Card Fail"},{"issue":"10","key":"2024111804013141700_dgae655-B86","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2024111804013141700_dgae655-B87","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"10","key":"2024111804013141700_dgae655-B88","first-page":"CD013650","article-title":"Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis","volume":"10","author":"Kanie","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"Supplement_1","key":"2024111804013141700_dgae655-B89","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.2337\/dc22-S010","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022","volume":"45","author":"Committee ADAPP","year":"2022","journal-title":"Diabetes Care"},{"issue":"7","key":"2024111804013141700_dgae655-B90","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.119.043594","article-title":"Women's participation in cardiovascular clinical trials from 2010 to 2017","volume":"141","author":"Jin","year":"2020","journal-title":"Circulation"},{"issue":"5","key":"2024111804013141700_dgae655-B91","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2337\/dc19-2257","article-title":"Sex disparities in cardiovascular outcome trials of populations with diabetes: a systematic review and meta-analysis","volume":"43","author":"Clemens","year":"2020","journal-title":"Diabetes Care"},{"issue":"2","key":"2024111804013141700_dgae655-B92","doi-asserted-by":"crossref","first-page":"bvac191","DOI":"10.1210\/jendso\/bvac191","article-title":"Sodium-glucose cotransporter-2 inhibition benefits in cardiorenal risk in men and women","volume":"7","author":"Pruett","year":"2022","journal-title":"J Endocr Soc"},{"issue":"3","key":"2024111804013141700_dgae655-B93","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3390\/jpm12030454","article-title":"Sex differences in response to treatment with glucagon-like peptide 1 receptor agonists: opportunities for a tailored approach to diabetes and obesity care","volume":"12","author":"Rentzeperi","year":"2022","journal-title":"J Pers Med"},{"issue":"12","key":"2024111804013141700_dgae655-B94","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1177\/0091270011430504","article-title":"Dosing rationale for liraglutide in type 2 diabetes mellitus: a pharmacometric assessment","volume":"52","author":"Ingwersen","year":"2012","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"2024111804013141700_dgae655-B95","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s40262-016-0410-7","article-title":"Liraglutide 3.0\u2005mg for weight management: a population pharmacokinetic analysis","volume":"55","author":"Overgaard","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2024111804013141700_dgae655-B96","doi-asserted-by":"crossref","first-page":"1251798","DOI":"10.3389\/fendo.2023.1251798","article-title":"Predictors of weight reduction effectiveness of SGLT2 inhibitors in diabetes mellitus type 2 patients","volume":"14","author":"Danpanichkul","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2024111804013141700_dgae655-B97","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s00125-024-06099-3","article-title":"Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes","volume":"67","author":"Cardoso","year":"2024","journal-title":"Diabetologia"},{"key":"2024111804013141700_dgae655-B98","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.diabres.2016.08.011","article-title":"Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: a systematic review","volume":"121","author":"Bihan","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"2024111804013141700_dgae655-B99","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/dom.12000","article-title":"Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials","volume":"15","author":"Monami","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2024111804013141700_dgae655-B100","doi-asserted-by":"crossref","first-page":"6616693","DOI":"10.1155\/2021\/6616693","article-title":"The antiobesity effect of GLP-1 receptor agonists alone or in combination with metformin in overweight\/obese women with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"2021","author":"Lyu","year":"2021","journal-title":"Int J Endocrinol"},{"key":"2024111804013141700_dgae655-B101","doi-asserted-by":"crossref","first-page":"107845","DOI":"10.1016\/j.intimp.2021.107845","article-title":"The role of incretins and incretin-based drugs in autoimmune diseases","volume":"98","author":"Radbakhsh","year":"2021","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"2024111804013141700_dgae655-B102","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.3390\/ijms23084334","article-title":"The role of Glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome","volume":"23","author":"Bednarz","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"14","key":"2024111804013141700_dgae655-B103","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s40265-022-01779-z","article-title":"The effect of oral antidiabetic drugs on improving the endocrine and metabolic states in women with polycystic ovary syndrome: a systematic review and network meta-analysis","volume":"82","author":"Yang","year":"2022","journal-title":"Drugs"},{"issue":"6","key":"2024111804013141700_dgae655-B104","doi-asserted-by":"crossref","first-page":"e3682","DOI":"10.1002\/dmrr.3682","article-title":"Cardiometabolic effects of SGLT2 inhibitors on polycystic ovary syndrome","volume":"39","author":"Lempesis","year":"2023","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"2024111804013141700_dgae655-B105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12902-023-01500-5","article-title":"Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Endocr Disord"},{"issue":"5","key":"2024111804013141700_dgae655-B106","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1007\/s43032-023-01415-5","article-title":"Effect of SGLT2 inhibitors on improving glucolipid metabolism and reproductive hormone status in overweight\/obese women with PCOS: a systematic review and meta-analysis","volume":"31","author":"Zhang","year":"2024","journal-title":"Reprod Sci"},{"key":"2024111804013141700_dgae655-B107","doi-asserted-by":"crossref","first-page":"830401","DOI":"10.3389\/fendo.2022.830401","article-title":"A meta-analysis of the effect of sodium glucose cotransporter-2 inhibitors on metabolic parameters in patients with polycystic ovary syndrome","volume":"13","author":"Sinha","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2024111804013141700_dgae655-B108","doi-asserted-by":"crossref","first-page":"108270","DOI":"10.1016\/j.pharmthera.2022.108270","article-title":"Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities","volume":"239","author":"Shao","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"10","key":"2024111804013141700_dgae655-B109","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4330\/wjc.v13.i10.585","article-title":"Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of cardiovascular outcome trials","volume":"13","author":"Patoulias","year":"2021","journal-title":"World J Cardiol"},{"issue":"1","key":"2024111804013141700_dgae655-B110","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12933-020-01133-1","article-title":"Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis","volume":"19","author":"D'Andrea","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"2024111804013141700_dgae655-B111","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.dsx.2020.02.012","article-title":"Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio-vascular outcome trials","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes & Metabolic Syndrome"},{"issue":"3","key":"2024111804013141700_dgae655-B112","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.pcd.2022.03.012","article-title":"Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes","volume":"16","author":"Mishriky","year":"2022","journal-title":"Prim Care Diabetes"},{"issue":"1","key":"2024111804013141700_dgae655-B113","doi-asserted-by":"crossref","first-page":"101160","DOI":"10.1016\/j.diabet.2020.05.002","article-title":"Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis","volume":"47","author":"Mishriky","year":"2021","journal-title":"Diabetes Metab"},{"issue":"1","key":"2024111804013141700_dgae655-B114","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40119-016-0075-1","article-title":"Does gender influence the cardiovascular benefits observed with sodium glucose co-transporter-2 (SGLT-2) inhibitors? A meta-regression analysis","volume":"6","author":"Mahmoud","year":"2017","journal-title":"Cardiol Ther"},{"issue":"1","key":"2024111804013141700_dgae655-B115","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ihj.2020.12.012","article-title":"Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: an updated meta-analysis","volume":"73","author":"Patoulias","year":"2021","journal-title":"Indian Heart J"},{"issue":"2","key":"2024111804013141700_dgae655-B116","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/dom.13876","article-title":"Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men","volume":"22","author":"R\u00e5dholm","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"Supplement_2","key":"2024111804013141700_dgae655-B117","doi-asserted-by":"crossref","first-page":"ehad655.984","DOI":"10.1093\/eurheartj\/ehad655.984","article-title":"Sex differences for the efficacy of sodium-glucose cotransporter 2 inhibitors on cardiorenal outcomes: a systematic review and meta-analysis","volume":"44","author":"Yamashita","year":"2023","journal-title":"Eur Heart J"},{"key":"2024111804013141700_dgae655-B118","first-page":"100261","article-title":"Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: a systematic review and meta-analysis","volume":"26","author":"Rivera","year":"2023","journal-title":"Am Heart J Plus"},{"issue":"1","key":"2024111804013141700_dgae655-B119","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12933-021-01276-9","article-title":"SGLT2 inhibitors and lower limb complications: an updated meta-analysis","volume":"20","author":"Lin","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"2024111804013141700_dgae655-B120","doi-asserted-by":"crossref","first-page":"e13997","DOI":"10.1111\/eci.13997","article-title":"Meta-analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus","volume":"53","author":"Mahmoud","year":"2023","journal-title":"Eur J Clin Invest"},{"issue":"15","key":"2024111804013141700_dgae655-B121","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1177\/2047487317729252","article-title":"Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR\u00ae Research to Practice project","volume":"24","author":"Arnold","year":"2017","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"2024111804013141700_dgae655-B122","doi-asserted-by":"crossref","first-page":"e001486","DOI":"10.1136\/bmjdrc-2020-001486","article-title":"The DIVE\/DPV registries: evolution of empagliflozin use in clinical practice in Germany","volume":"8","author":"Bramlage","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"4","key":"2024111804013141700_dgae655-B123","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2337\/dc19-1943","article-title":"Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013-2018","volume":"43","author":"Dave","year":"2020","journal-title":"Diabetes Care"},{"issue":"1","key":"2024111804013141700_dgae655-B124","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12933-022-01713-3","article-title":"Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study","volume":"21","author":"Funck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"2024111804013141700_dgae655-B125","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1089\/jwh.2023.0059","article-title":"Sex-related disparities in prescription patterns of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and heart failure","volume":"32","author":"Hammer","year":"2023","journal-title":"J Womens Health (Larchmt)"},{"issue":"4","key":"2024111804013141700_dgae655-B126","doi-asserted-by":"crossref","first-page":"e216139","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2024111804013141700_dgae655-B127","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12902-019-0334-y","article-title":"Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas","volume":"19","author":"Roberto","year":"2019","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"2024111804013141700_dgae655-B128","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11606-021-07227-0","article-title":"Longer-term benefits and risks of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes: a systematic review and meta-analysis","volume":"37","author":"Alexander","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"1","key":"2024111804013141700_dgae655-B129","doi-asserted-by":"crossref","first-page":"e001238","DOI":"10.1136\/bmjdrc-2020-001238","article-title":"Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation","volume":"8","author":"McGovern","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"5","key":"2024111804013141700_dgae655-B130","doi-asserted-by":"crossref","first-page":"bvaa037","DOI":"10.1210\/jendso\/bvaa037","article-title":"Glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter inhibitors for treatment of T2DM","volume":"4","author":"McKee","year":"2020","journal-title":"J Endocr Soc"},{"key":"2024111804013141700_dgae655-B131","first-page":"100692","article-title":"Sex differences in risk of cardiovascular events and mortality with sodium glucose co-transporter-2 inhibitors versus glucagon-like peptide 1 receptor agonists in Australians with type 2 diabetes: a population-based cohort study","volume":"33","author":"Sharma","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"2024111804013141700_dgae655-B132","doi-asserted-by":"crossref","first-page":"e012940","DOI":"10.1161\/JAHA.119.012940","article-title":"Sex differences in cardiovascular effectiveness of newer glucose-lowering drugs added to metformin in type 2 diabetes mellitus","volume":"9","author":"Raparelli","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2024111804013141700_dgae655-B133","doi-asserted-by":"crossref","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"issue":"3","key":"2024111804013141700_dgae655-B134","doi-asserted-by":"crossref","first-page":"e061807","DOI":"10.1136\/bmjopen-2022-061807","article-title":"Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight\/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis","volume":"13","author":"Ma","year":"2023","journal-title":"BMJ Open"},{"issue":"3","key":"2024111804013141700_dgae655-B135","doi-asserted-by":"crossref","first-page":"e14780","DOI":"10.1111\/dme.14780","article-title":"Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials","volume":"39","author":"Sim","year":"2022","journal-title":"Diabet Med"},{"issue":"1","key":"2024111804013141700_dgae655-B136","doi-asserted-by":"crossref","first-page":"17545","DOI":"10.1038\/s41598-020-74000-4","article-title":"Gender differences in adverse event reports associated with antidiabetic drugs","volume":"10","author":"Joung","year":"2020","journal-title":"Sci Rep"},{"issue":"5","key":"2024111804013141700_dgae655-B137","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/dom.12872","article-title":"Upper and\/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: incidence and consequences","volume":"19","author":"Horowitz","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2024111804013141700_dgae655-B138","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00228-020-03051-3","article-title":"Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review","volume":"77","author":"Bamgboye","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"2024111804013141700_dgae655-B139","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bcp.13782","article-title":"Increased risk of mycotic infections associated with sodium-glucose co-transporter 2 inhibitors: a prescription sequence symmetry analysis","volume":"85","author":"Adimadhyam","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2024111804013141700_dgae655-B140","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11892-024-01537-3","article-title":"Diabetes, SGLT-2 inhibitors, and urinary tract infection: a review","volume":"24","author":"Pishdad","year":"2024","journal-title":"Curr Diabetes Rep"},{"issue":"3","key":"2024111804013141700_dgae655-B141","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2337\/dc21-1676","article-title":"Three sides to the story: adherence trajectories during the first year of SGLT2 inhibitor therapy among Medicare beneficiaries","volume":"45","author":"Hawley","year":"2022","journal-title":"Diabetes Care"},{"key":"2024111804013141700_dgae655-B142","doi-asserted-by":"crossref","first-page":"100627","DOI":"10.1016\/j.lanepe.2023.100627","article-title":"Underuse of glucose-lowering medications associated with cardiorenal protection in type 2 diabetes: from delayed initiation to untimely discontinuation","volume":"29","author":"Scheen","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"11","key":"2024111804013141700_dgae655-B143","first-page":"1242","article-title":"Individual and social determinants of adherence to sodium-glucose cotransporter 2 inhibitor therapy: a trajectory analysis","volume":"29","author":"Yang","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"2024111804013141700_dgae655-B144","doi-asserted-by":"crossref","first-page":"111689","DOI":"10.1016\/j.diabres.2024.111689","article-title":"Real-world sex differences in type 2 diabetes patients treated with GLP-1 receptor agonists","volume":"212","author":"Piccini","year":"2024","journal-title":"Diabetes Res Clin Pract"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae655\/59640294\/dgae655.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/12\/e2167\/60680362\/dgae655.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/12\/e2167\/60680362\/dgae655.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T23:02:50Z","timestamp":1731884570000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/12\/e2167\/7765949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":144,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,9,23]]},"published-print":{"date-parts":[[2024,11,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae655","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,9,23]]}}}